Atyr Pharma Inc. 8-K Summary
Business Context and Reporting Period
Atyr Pharma, Inc. filed this Current Report on Form 8-K on November 18, 2016, to disclose the entry into a new material definitive agreement and the termination of a prior loan agreement. The company is a Delaware corporation headquartered in San Diego, California.
Key Financial Metrics and Transaction Details
- New Debt Facility: Entered into a Loan and Security Agreement for a total facility of up to $20.0 million with Silicon Valley Bank (SVB) and Solar Capital Ltd.
- Initial Funding: The First Tranche of $10.0 million was funded on November 18, 2016.
- Future Tranches: A Second Tranche of $5.0 million (available before June 30, 2017) and a Third Tranche of $5.0 million (available after June 30, 2017) are contingent on achieving specific financial and clinical milestones.
- Interest Rate: Prime Rate plus 4.10%.
- Final Payment: A final interest payment equal to 8.75% of the funded amount is due at maturity or prepayment.
- Repayment Schedule: Interest-only payments through December 1, 2017 (or June 1, 2018 if the Second Tranche is drawn), followed by monthly principal and interest payments through maturity on November 18, 2020.
- Collateral: Security interest granted in substantially all assets except intellectual property, which is subject to a negative pledge.
- Warrants Issued: Warrants to purchase 47,771 shares each to SVB and Solar (95,542 total) at an exercise price of $3.14 per share, expiring November 18, 2023.
- Debt Repayment: Approximately $2.6 million of the initial $10.0 million tranche was used to fully repay a prior loan from SVB.
Material Changes Versus Prior Period
The company terminated its prior Loan and Security Agreement dated April 25, 2012 (as amended), replacing it with the new facility. No termination fees were paid for the prior agreement. The new agreement introduces milestone-based funding tranches and a higher interest rate structure compared to the prior arrangement.
Guidance, Risks, and Covenants
- Covenants: The agreement includes affirmative covenants (information delivery, insurance maintenance) and negative covenants (restrictions on additional indebtedness, mergers, and liens).
- Banking Requirements: The company must maintain its primary deposit, securities, and commodity accounts with SVB.
- Default Provisions: Events of default include failure to fulfill obligations, material adverse changes, or impairment of collateral. A default interest rate of an additional 5.0% applies upon default.
- Non-Usage Fee: A 2.0% fee applies to any unfunded amounts if the Second or Third Tranches are not drawn.
- Prepayment: Prepayment is permitted subject to a fee ranging from 1.0% to 3.0% depending on the timing.
Investor Verification Checklist
- Verify the specific financial and clinical milestones required to draw the Second and Third Tranches.
- Confirm the current Prime Rate to calculate the effective interest cost.
- Review the impact of the 8.75% final interest payment on total debt service costs.
- Assess the dilution impact of the 95,542 warrants issued at $3.14 per share.
- Monitor the company's ability to maintain the required primary deposit accounts with SVB.